Jan 28 (Reuters) –

* NOVAVAX SAYS COVID-19 VACCINE CANDIDATE NVX-COV2373 MET PRIMARY ENDPOINT, WITH VACCINE EFFICACY OF 89.3%, IN PHASE 3 CLINICAL TRIAL CONDUCTED IN UK

* NOVAVAX SAYS NVX-COV2373 SHOWED STRONG EFFICACY IN PHASE 3 UK TRIAL WITH OVER 50% OF CASES ATTRIBUTABLE TO NOW-PREDOMINANT UK VARIANT

* NOVAVAX SAYS VACCINE DEMONSTRATES CLINICAL EFFICACY AGAINST COVID-19 AND BOTH UK AND SOUTH AFRICA VARIANTS

* NOVAVAX SAYS CLINICAL EFFICACY SHOWN IN PHASE 2B SOUTH AFRICA TRIAL WITH OVER 90% OF SEQUENCED CASES ATTRIBUTABLE TO SOUTH AFRICA ESCAPE VARIANT

* NOVAVAX SAYS VACCINE CANDIDATE STABLE AT 2°C TO 8°C (REFRIGERATED) & IS SHIPPED IN READY-TO-USE LIQUID FORMULATION

* NOVAVAX – ADDITIONAL ANALYSIS ON UK, SOUTH AFRICA TRIALS ONGOING, WILL BE SUBMITTED TO PEER-REVIEWED JOURNAL FOR PUBLICATION

* NOVAVAX – SOUTH AFRICA CLINICAL TRIAL ACHIEVED PRIMARY EFFICACY ENDPOINT IN OVERALL TRIAL POPULATION, INCLUDING HIV-POSITIVE & HIV-NEGATIVE SUBJECTS

* NOVAVAX – EXPECTS TO SELECT IDEAL CANDIDATES FOR A BOOSTER AND/OR COMBINATION BIVALENT VACCINE FOR NEW STRAINS IN COMING DAYS

* NOVAVAX – PLANS TO INITIATE CLINICAL TESTING OF NEW VACCINES IN Q2 Source text for Eikon:

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html